Overview
- The Medicines and Healthcare products Regulatory Agency authorised orforglipron, sold as Foundayo, on Monday, making the UK the first regulator in Europe to clear the oral GLP‑1 for weight management and type 2 diabetes.
- Eli Lilly plans a private launch in the UK later this month, while routine NHS availability will await an independent assessment by the National Institute for Health and Care Excellence.
- Foundayo is a once‑daily GLP‑1 receptor agonist taken in a stepwise dose escalation from 0.8 mg to 17.2 mg, and it can be swallowed at any time without food or water restrictions.
- Common side effects include nausea, constipation, diarrhoea, vomiting, dyspepsia and abdominal pain, and the MHRA said it will continue post‑authorisation safety monitoring and urged reports to the Yellow Card scheme.
- The approval intensifies competition in the growing oral GLP‑1 market after Novo Nordisk’s Wegovy pill, with near‑term private availability, pricing pressure and NHS budget decisions set to shape patient access.